Abstract: The present invention provides cryptophycin compounds of Formula I that are useful in the treatment of neoplasms.

Abstract: This invention provides certain substituted benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.

Abstract: Novel processes and intermediates useful in the preparation of Cryptophycin compounds are disclosed.

Abstract: This invention provides certain substituted 2,3-dihydrobenzofurylsulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier.

Abstract: This invention provides for crystalline hydrochloride C.sub.1 -C.sub.3 alcohol solvate forms of the compound of formula (I): ##STR1## In particular, crystalline hydrochloride ethanol, methanol, and propanol solvates are disclosed.

Abstract: This invention provides certain benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier, and processes for preparing the benzenesulfonamide derivatives.

Abstract: This invention provides for crystalline hydrochloride C.sub.1 -C.sub.3 alcohol solvate forms of the compound of formula (I): ##STR1## In particular, crystalline hydrochloride ethanol, methanol, and propanol solvates are disclosed. Also disclosed are processess for preparing and using the above compounds.

Abstract: This invention provides certain sulfonamidoquinoxaline derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these sulfonamidoquinoxaline derivatives, in combination with a carrier, diluent or excipient.

Abstract: This invention provides certain N-phenyl-N'-substituted phenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.

Abstract: This invention provides the use of certain indenesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel indenesulfonamide derivatives and their pharmaceutical formulations.

Abstract: This invention provides certain sulfonimidamide compounds, formulations and method of use of these compounds in treating susceptible neoplasms.

Abstract: This invention provides the use of N-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3-dihydrobenzofuran-5-sulfonamid e, and pharmaceutically acceptable salts thereof, in the treatment of susceptible neoplasms in mammals. This invention further provides the novel aforementioned compound and its pharmaceutical formulations.

Abstract: This invention provides certain N-phenyl-N'-substitutedphenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.

Abstract: A locking mechanism for a mobile safe having at least one loading door for depositing valuables such as cash within the safe and at least one unloading door for emptying the safe includes an actuating mechanism for moving the loading door between its open and closed positions. The actuating mechansim extends out of the safe for engagement with a vault door locking mechanism when the safe is placed within an outer vault for secure deposit of cash into the safe. The engagement is such that the actuating mechanism operates to open the loading door as the vault door is locked. A locking device associated with the actuating mechanism automatically locks the safe door in its closed position and can only be released by subsequent unlocking or opening of the unloading door by a person having the required key.

Abstract: An improved method of preparing 23-monoester derivatives of 5-O-mycaminosyl tylonolide (OMT) and demycinosyltylosin (DMT) is provided. This method comprises esterifying the antibiotic with an acylating agent in the presence of an external base, such as pyridine or 2,4,6-collidine, until acylation of the 23-hydroxyl group is substantially complete, and separating the 23-monoester derivative. 23-Monoester derivatives of OMT and DMT are useful antibiotics and/or intermediates to antibiotics.

Abstract: C-20- and C-23-Modified macrolide derivatives of demycinosyltylocin (DMT), 5-O-mycaminosyltylonolide (OMT) 23-de(mycinosyloxy)tylosin, 23-deoxy-OMT, 20-dihydro-20-deoxy-DMT and 20-dihydro-20-deoxy-OMT are useful antibiotics or intermediates to antibiotics.

Abstract: C-23-Modified derivatives of 5-O-mycaminosyl-tylonolide (OMT) of the formula: ##STR1## wherein R is chloro, fluoro, --S--R.sup.4, azido, --NHR.sup.5, pyridinium, or --OSO.sub.2 CF.sub.3 ;R.sup.1 is hydrogen, optionally substituted C.sub.1 -C.sub.5 -alkanoyl or optionally substituted benzoyl, phenylacetyl, phenylpropionyl, phenoxyacetyl or phenylthioacetyl;R.sup.2 and R.sup.3 are hydrogen, optionally substituted C.sub.1 -C.sub.5 -alkanoyl or optionally substituted benzoyl, phenylacetyl or phenylpropionyl;R.sup.4 is hydrogen, optionally substituted C.sub.1 -C.sub.6 -alkyl, cyclohexyl, C.sub.1 -C.sub.5 alkanoyl, optionally substituted phenyl or benzyl, or an optionally substituted heteroaryl group selected from imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, thienyl and furanyl; andR.sup.5 is hydrogen or an acyl group selected from optionally substituted C.sub.1 -C.sub.

Abstract: C-23-Modified derivatives of demycinosyltylosin (DMT) of the formula: ##STR1## wherein R is iodo, bromo, chloro, fluoro, --S--R.sup.4, azido, --NHR.sup.5, pyridinium or --OSO.sub.2 CF.sub.3 ;R.sup.1 is hydrogen, optionally substituted C.sub.1 -C.sub.5 -alkanoyl or optionally substituted benzoyl, phenylacetyl, phenylpropionyl, phenoxyacetyl or phenylthioacetyl;R.sup.2 is hydrogen, optionally substituted C.sub.1 -C.sub.5 -alkanoyl or optionally substituted benzoyl, phenylacetyl or phenylpropionyl;R.sup.3 is hydrogen, optionally substituted C.sub.1 -C.sub.5 -alkanoyl or optionally substituted benzoyl, phenylacetyl or phenoxyacetyl;R.sup.4 is hydrogen, optionally substituted C.sub.1 -C.sub.6 -alkyl, cyclohexyl, C.sub.1 -C.sub.

Abstract: C-20-Modified derivatives of the macrolide antibiotics tylosin, desmycosin, macrocin, lactenocin, 2"'-O-demethylmacrocin and 2"-O-demethyllactenocin inhibit pathogenic bacteria, especially gram-positive bacteria, Pasteurella species, and Mycoplasma species and pharmaceutical compositions thereof.

Abstract: A thermal printing system in which printing speed is maximized by electronically controlling the temperature of the print elements in accordance with the varying dot pattern being printed. The system includes a thermal printer module and a printer circuit which are specially adapted to be utilized in a modularized device such as a ticket vending machine. The printer circuit includes a microprocessor which demodulates serial data commands and stores the demodulated data in an input buffer. The microprocessor decodes the information in the input buffer and sets up an output buffer containing character data to be printed on the ticket. The microprocessor causes the character data stored in the output buffer to be printed on the ticket using software timing loops to selectively control the temperature of the individual print elements.